Inhibition of type I interferon signaling is a conserved function of gamma-herpesvirus-encoded microRNAs
Journal of Virology · 2026
DOI: 10.1128/jvi.01579-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2026. Verfasst von Devin N Fachko und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Gene Therapy Institute, Beaverton, Oregon, USA. Hauptthemen laut MEDLINE: MicroRNAs, Interferon Type I, Signal Transduction, Gammaherpesvirinae. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Herpesviruses encode multiple factors that disarm innate immune signaling to evade host anti-viral responses. Several viral microRNAs expressed by Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) disrupt the induction of type I interferons (IFN) and/or the subsequent signaling events activated through type I IFN receptors. Here, we aimed to determine whether non-human primate (NHP) γ-herpesviruses (rhesus lymphocryptovirus [rLCV], rhesus rhadinovirus [RRV], and Japanese macaque rhadinovirus [JMRV]), closely related to EBV and KSHV, use similar microRNA (miRNA)-mediated strategies to regulate IFN responses. Through functional screens, we identified multiple viral miRNAs that attenuated type I IFN-mediated activation of an IFN-stimulated response element reporter and diminished expression of interferon-stimulated genes (ISGs). Infection of primary cells with miRNA-deficient rLCVs resulted in augmented expression of ISGs. Abrogation of EBV BART miRNA homologs from rLCV, in particular, led to heightened sensitivity of latently infected cells to exogenous type I IFN. Through sequence analysis and reporter assays, we show that targets of these viral miRNAs include transcripts encoding the type I IFN receptors (IFNAR1, IFNAR2) and core components of JAK/STAT signaling pathways (JAK1, IRF9). Taken together, these data demonstrate that suppression of type I IFN responses is a conserved function for NHP γ-herpesvirus miRNAs and provide important mechanistic insight into how these viral miRNAs regulate type I IFN signaling pathways. IMPORTANCE Gamma-herpesviruses establish life-long infections in their hosts. Evading anti-viral responses is a key component of long-term viral persistence. In this work, we show that small noncoding RNAs expressed by multiple non-human primate γ-herpesviruses regulate anti-viral responses by directly targeting components of the type I interferon (IFN) signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccine and Gene Therapy Institute, Beaverton, Oregon, USA.
- Gundersen Medical Foundation, La Crosse, Wisconsin, USA.
- Oregon National Primate Research Center, Beaverton, Oregon, USA.
ORCID-Profile: Devin N Fachko, Bonnie Goff, Darby G Oldenburg, Ryan D Estep, Scott W Wong, Rebecca L Skalsky
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Cancer Institute
Zitieren
APA
Fachko, D. N., Chen, Y., Ivanov, N. S., Goff, B., Pendergrass, B., Oldenburg, D. G., Estep, R. D., Wong, S. W., & Skalsky, R. L. (2026). Inhibition of type I interferon signaling is a conserved function of gamma-herpesvirus-encoded microRNAs. Journal of Virology. https://doi.org/10.1128/jvi.01579-25
Vancouver
Fachko DN, Chen Y, Ivanov NS, Goff B, Pendergrass B, Oldenburg DG, et al. Inhibition of type I interferon signaling is a conserved function of gamma-herpesvirus-encoded microRNAs. Journal of Virology. 2026. doi:10.1128/jvi.01579-25
BibTeX
@article{Fachko2026,
author = {Fachko, Devin N and Chen, Yan and Ivanov, Nikita S and Goff, Bonnie and Pendergrass, Brian and Oldenburg, Darby G and Estep, Ryan D and Wong, Scott W and Skalsky, Rebecca L},
title = {Inhibition of type I interferon signaling is a conserved function of gamma-herpesvirus-encoded microRNAs},
journal = {Journal of Virology},
year = {2026},
doi = {10.1128/jvi.01579-25}
}
EUVIMED